Some of the biggest challenges executives of early-stage life sciences companies face is securing financing and forging their first licensing deals. Though they may possess deep scientific knowledge, finding the right investors and partners, and telling their story in a compelling way may require skills they have not yet developed. Life Science Nation works with entrepreneurs to tell their story, identify potential investors and partners, and connect with them. We spoke to Dennis Ford, founder and CEO of Life Science Nation, about the mistakes life sciences entrepreneurs make when they set out to raise money, what investors care about, and what steps they can take to best ensure their success.

Bold Therapeutics is a clinical-stage pharma startup developing and commercializing novel therapeutics to combat drug resistance in cancer and infectious disease. At Digital RESI March, Bold Therapeutics founder Russell McAllister met success at the Innovator’s Pitch Challenge (IPC) and is sharing his perspectives from preparation to pitch to follow-up conversations. If you’re actively fundraising or considering pitching at RESI, check out our conversation and learn how Russell leveraged, not only his company, but his own unique experience to stand out at RESI.

Amplified Sciences CEO and Co-Founder, Diana Caldwell knows a lot about lasting impressions. It was an early impression working with her co-founder, Dr. Jo Davisson that led her to join him in leading Amplified Sciences and advancing the early detection of devastating diseases, such as pancreatic cancer. Additionally, Diana’s recent first-place win at the Digital RESI JPM Innovator’s Pitch Challenge (IPC) was a result of the impressions she left with judges and attendees alike with marketing materials and a live pitch.

Listen to our conversation to learn more about Diana’s career as a pharma executive and how her experience and passion led her to her latest adventure: entrepreneurship, fundraising, changing the diagnostic landscape, and leaving all the right impressions along the way.

David Dlesk is a seasoned entrepreneur and investor, passionate about therapeutic innovation, which has led him to co-found Embrace Prevention Care, a company dedicated to safe and effective medication adherence for older adults. David has decades of experience in early-stage life science and healthcare, and has learned how to lead, connect, and accept sound advice.

KYTO Technology & Life Science is not your typical investment firm. They have a unique model that focuses on the financial investment, mentorship and advising, as well as growth and success of early-stage life science technology and their founding teams. Tom Vogelsong is the Director of Deal Flow and he sat down to discuss what makes KYTO’s outlook and processes different, the unique value they add to their portfolio, and exciting developments in the works.

Larry Raoul James is no stranger to challenge, rejection, and powering through. His company, MindLab has developed a pain management therapeutic designed to prevent tolerance, dependence, and addiction in patients, while sustaining current efficacy standards. With recent endorsement from the US Army Medical Research & Development Command (a connection made through a recent RESI conference), Larry and the MindLab team are not slowing down. Despite the challenges associated with bringing novel therapeutics to market, they are working hard to meet a persistent and growing need for safe alternatives to pain medication.

Listen to a recent interview with Larry on the MindLab journey.

Virtual fundraising is not dead. It’s alive and well for 2022. In this conversation with LSN CEO, Dennis Ford discusses the virtual fundraising model and how Digital RESI JPM stands out as a vehicle for connecting ideas and capital in early-stage life science and healthcare.